<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548871" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548871/" /><meta name="ncbi_pagename" content="Buprenorphine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Buprenorphine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Buprenorphine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/11/24" /><meta name="citation_pmid" content="31644178" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548871/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Buprenorphine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/11/24" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548871/" /><meta name="description" content="Buprenorphine is a sublingually and transdermally available, semisynthetic opioid analgesic, which is used as an analgesic and for management of opioid dependence. Therapy with buprenorphine is associated with mild and transient serum enzyme elevations, and with moderate-to-severe clinically apparent liver injury when abused by intravenous administration or the sublingual formations." /><meta name="og:title" content="Buprenorphine" /><meta name="og:type" content="book" /><meta name="og:description" content="Buprenorphine is a sublingually and transdermally available, semisynthetic opioid analgesic, which is used as an analgesic and for management of opioid dependence. Therapy with buprenorphine is associated with mild and transient serum enzyme elevations, and with moderate-to-severe clinically apparent liver injury when abused by intravenous administration or the sublingual formations." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548871/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Buprenorphine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548871/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B320904669E310000000003930110.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548871_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548871_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Budesonide/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Bupropion/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548871_"><span class="title" itemprop="name">Buprenorphine</span></h1><p class="small">Last Update: <span itemprop="dateModified">November 24, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Buprenorphine.OVERVIEW"><h2 id="_Buprenorphine_OVERVIEW_">OVERVIEW</h2><div id="Buprenorphine.Introduction"><h3>Introduction</h3><p>Buprenorphine is a sublingually and transdermally available, semisynthetic opioid analgesic, which is used as an analgesic and for management of opioid dependence. Therapy with buprenorphine is associated with mild and transient serum enzyme elevations, and with moderate-to-severe clinically apparent liver injury when abused by intravenous administration or the sublingual formations.</p></div><div id="Buprenorphine.Background"><h3>Background</h3><p>Buprenorphine (bue" pre nor' feen) is a semisynthetic opioid that is 25 to 50 times more potent than morphine and has been used as an analgesic as well as therapy of opioid addiction. Buprenorphine is a partial &#x000b5;-opioid receptor agonist and a &#x003ba;-receptor antagonist accounting for its benefit for opioid deterrence. Buprenorphine competes with morphine and heroin for the &#x000b5; receptor, but is only a partial agonist and has a &#x0201c;ceiling&#x0201d; effect. Buprenorphine was approved for treatment of opioid addiction in 2004 and is a schedule III controlled substance. Current indications include treatment of moderate-to-severe pain (parenterally in low doses &#x0003c;1 mg) and opiate addiction (in various formulations in higher doses 2 to 16 mg daily). Buprenorphine is available as 2 and 8 mg tablets for sublingual administration generically and under the brand name Subutex, and in 1 mL ampules of 0.3 mg/mL for intravenous (iv) or intramuscular (im) injection generically and under the brand name Buprenex. More recently, buccal film formulations, transdermal patches (Butrans and generics), once monthly prolonged release injections (Sublocade) and once every 6 months implants injected subcutaneously (Probuphine) with buprenorphine have become available as therapy for opioid dependence. Buprenorphine is also available in fixed combination with naloxone (tablets and buccal films: 2 mg/0.5 mg and 8 mg/2 mg) for sublingual administration generically and under the brand name Suboxone. Naloxone is not absorbed orally, but provides full opioid antagonism if the combination is administer intravenously, as might occur with intentional abuse. Oral naloxone may also help to alleviate the gastrointestinal side effects of opioids such as constipation, nausea, vomiting and abdominal bloating. Finally, parenteral forms of buprenorphine are used for moderate-to-severe pain and administered iv or im, the typical dose being 0.3 mg every 6 hours as needed. Common side effects of buprenorphine include headache, dizziness, fatigue, sedation, dry mouth, urinary retention, diaphoresis, orthostatic hypotension, biliary spasm and withdrawal symptoms. Rare but potentially severe adverse reactions include life threatening respiratory and CNS depression, hepatotoxicity, adrenal insufficiency, interactions with other sedative medications, unintentional pediatric exposure and neonatal opioid withdrawal syndrome. Buprenorphine should be prescribed only by a health care provider with training in opioid dependency and managing the dosing and side effects of buprenorphine and naloxone.</p></div><div id="Buprenorphine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Buprenorphine therapy has been associated with a low rate of serum enzyme elevations during treatment, although the populations studied (opioid dependent) often have coexisting chronic liver diseases which complicate such assessments. Nevertheless, rates of <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations during treatment with buprenorphine (with or without naloxone) have been minimally or no greater than with comparator arms (methadone).</p><p>In addition, there have been several reports and case series of acute, clinically apparent liver injury arising within 2 to 20 weeks of starting buprenorphine, usually (but not invariably) following misuse and intravenous administration of sublingual tablets. However, some cases occurred in patients who denied intravenous use and were on conventional sublingual doses. In most cases, the pattern of serum enzyme elevations was hepatocellular and the presentation resembled acute toxic hepatic necrosis. Immunoallergic features (fever, rash and eosinophilia) were not present, nor were autoantibodies detected. Almost all patients with this injury had concurrent chronic hepatitis C, and several appeared to resolve the chronic infection with the acute liver injury (Case 1). Strikingly, most patients were able to continue buprenorphine without recurrence, some of whom admitted to continued intravenous abuse.</p><p>Likelihood score: B[HD] (likely rare cause of clinically apparent liver injury usually associated with overdose or misuse).</p></div><div id="Buprenorphine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Buprenorphine undergoes extensive first pass hepatic extraction and is metabolized primarily by the cytochrome P450 system (CYP 3A4). The low doses used and rapid metabolism may account for its relative lack of hepatotoxicity when used in conventional doses. The appearance of an acute hepatic necrosis after intravenous injection of the sublingual tablets is likely due to direct toxicity of these high parenteral doses. The occurrence of this syndrome largely in patients with concurrent hepatitis C remains unexplained. Clearance of hepatitis C during this toxic injury raises the issue of whether the acute injury is actually due to an exacerbation of hepatitis C or whether the severe acute toxic injury can induce viral clearance.</p></div><div id="Buprenorphine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The severity of liver injury attributed to buprenorphine has ranged from mild-to-severe hepatitis, and fatal instances have been reported. Interestingly, most patients subsequently tolerated restarting buprenorphine at doses used prior to the toxic event, and some patients continued to misuse it by intravenous injection, but did not have recurrence of the liver injury.</p><p>Drug Class: <a href="/books/n/livertox/SubstanceAbuseTreatm/">Substance Abuse Treatment Agents</a>; <a href="/books/n/livertox/Opioids/">Opioids</a></p></div></div><div id="Buprenorphine.CASE_REPORT"><h2 id="_Buprenorphine_CASE_REPORT_">CASE REPORT</h2><div id="Buprenorphine.Case_1_Acute_liver_injury"><h3>Case 1. Acute liver injury attributed to buprenorphine use in a patient with chronic hepatitis C.(<a class="bk_pop" href="#Buprenorphine.REF.1">1</a>)</h3><p>A 33 year old male injection drug user with chronic hepatitis C (HCV genotype 1a) developed jaundice, abdominal pain and fever shortly after injecting 3 to 5 crushed and dissolved tablets of buprenorphine (8 mg, meant for sublingual administration) intravenously. He was known to have chronic hepatitis C, but had never been treated for the infection which was considered mild. He had no other history of liver disease but consumed alcohol regularly. He took no other medications. On admission, laboratory tests showed a serum bilirubin of 29.6 mg/dL with marked elevations in serum aminotransferase levels (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 4132 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 3947 U/L) and mild increases in alkaline phosphatase (347 U/L) and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> (127 U/L; normal &#x0003c;50) (Table). The prothrombin index was 43% of control (INR 1.7). A transjugular liver biopsy showed panlobular necrosis, diffuse lobular inflammation, and marked cholestasis indicative of acute hepatic injury. In addition, there was moderate portal fibrosis and portal inflammation suggestive of an underlying chronic hepatitis C. Tests for hepatitis A and B and HIV were negative. Anti-HCV was present, but serum HCV RNA was present at very low levels (15 IU/mL). <a class="def" href="/books/n/livertox/glossary/def-item/glossary.jaundice/">Jaundice</a> resolved within a week and serum enzymes fell rapidly. Sublingual buprenorphine was restarted without a change in the pattern of recovery. In follow up 3 months later, serum ALT levels were normal and HCV RNA was undetectable. When seen almost a year later, he admitted to continuing to self-inject buprenorphine, yet serum ALT levels were still normal and HCV RNA was undetectable.</p><div id="Buprenorphine.Key_Points"><h4>Key Points</h4><div id="Buprenorphine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548871/table/Buprenorphine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Buprenorphine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Buprenorphine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Buprenorphine.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Buprenorphine (24 mg intravenously)</td></tr><tr><th id="hd_b_Buprenorphine.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Buprenorphine.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=31)</td></tr><tr><th id="hd_b_Buprenorphine.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Buprenorphine.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4+ (jaundice and prolongation of INR)</td></tr><tr><th id="hd_b_Buprenorphine.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Buprenorphine.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Short, specific time not provided</td></tr><tr><th id="hd_b_Buprenorphine.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Buprenorphine.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rapid, within 1-2 months</td></tr><tr><th id="hd_b_Buprenorphine.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Buprenorphine.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></div><div id="Buprenorphine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Buprenorphine.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548871/table/Buprenorphine.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Buprenorphine.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Buprenorphine.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Buprenorphine.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Buprenorphine.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Buprenorphine.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Buprenorphine.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Buprenorphine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Buprenorphine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4132</td><td headers="hd_h_Buprenorphine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">347</td><td headers="hd_h_Buprenorphine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">29.6</td><td headers="hd_h_Buprenorphine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Buprenorphine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 days</td><td headers="hd_h_Buprenorphine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2546</td><td headers="hd_h_Buprenorphine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">288</td><td headers="hd_h_Buprenorphine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26.9</td><td headers="hd_h_Buprenorphine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.prothrombin-time/">Prothrombin time</a> 18 sec</td></tr><tr><td headers="hd_h_Buprenorphine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td><td headers="hd_h_Buprenorphine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">132</td><td headers="hd_h_Buprenorphine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Buprenorphine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.2</td><td headers="hd_h_Buprenorphine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Buprenorphine restarted</td></tr><tr><td headers="hd_h_Buprenorphine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_Buprenorphine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Buprenorphine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Buprenorphine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Buprenorphine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HCV RNA negative</td></tr><tr><td headers="hd_h_Buprenorphine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 months</td><td headers="hd_h_Buprenorphine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11</td><td headers="hd_h_Buprenorphine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Buprenorphine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Buprenorphine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HCV RNA negative</td></tr><tr><td headers="hd_h_Buprenorphine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>Normal</b></td><td headers="hd_h_Buprenorphine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Buprenorphine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;104</b></td><td headers="hd_h_Buprenorphine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Buprenorphine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Buprenorphine.Comment"><h4>Comment</h4><p>The clinical presentation of acute hepatic necrosis shortly after intravenous abuse of buprenorphine has been reported in several case reports and single center series of as many as 7 cases. Intriguingly, virtually all patients reported with this syndrome had a preexisting chronic hepatitis C, although many were HCV RNA negative at the time of the acute illness. The current case documents the loss of HCV RNA during the acute hepatic injury attributed to buprenorphine. Two explanations are possible. First, that the acute toxic hepatic injury caused an interruption in the replication of HCV or triggered host immune responses (the innate immune system and interferon production), resulting in clearance of hepatitis C. A second explanation is that the acute illness was due to an exacerbation of the chronic HCV infection, which led to an acute hepatitis C-like clearance of virus. The role of hepatitis C in this reaction is perhaps demonstrated best by the absence of recurrence of liver injury when buprenorphine was restarted and even when abused intravenously in high doses. The combination of buprenorphine with naloxone (a full &#x000b5; opioid receptor antagonist) was developed to discourage such intravenous abuse.</p></div></div></div><div id="Buprenorphine.PRODUCT_INFORMATION"><h2 id="_Buprenorphine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Buprenorphine &#x02013; Generic, Buprenex&#x000ae;, Subutex&#x000ae; (SL Tablets)</p><p>Buprenorphine/Naloxone &#x02013; Generic, Suboxone&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Substance Abuse Treatment Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Buprenorphine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Buprenorphine.CHEMICAL_FORMULA_AND_STRUC"><h2 id="_Buprenorphine_CHEMICAL_FORMULA_AND_STRUC_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Buprenorphine.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548871/table/Buprenorphine.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Buprenorphine.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Buprenorphine.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Buprenorphine.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Buprenorphine.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Buprenorphine.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Buprenorphine.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Buprenorphine</td><td headers="hd_h_Buprenorphine.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135002732" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">52485-79-7</a></td><td headers="hd_h_Buprenorphine.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C29-H41-N-O4</td><td headers="hd_h_Buprenorphine.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135002732" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135002732" alt="image 135002732 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Buprenorphine.CITED_REFERENCES"><h2 id="_Buprenorphine_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Buprenorphine.REF.1">Peyri&#x000e8;re H, Tatem L, Bories C, Pageaux GP, Blayac JP, Larrey D. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. <span><span class="ref-journal">Ann Pharmacother. </span>2009;<span class="ref-vol">43</span>:973–7.</span> [Modified from Case 1.] [<a href="/pubmed/19383935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19383935</span></a>]</div></dd></dl></div><div id="Buprenorphine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Buprenorphine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 24 November 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Buprenorphine.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<div><i>(Expert review of hepatotoxicity published in 1999 before the availability of buprenorphine).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.larrey.2013">Larrey D, Ripault M-P. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 443-62.<div><i>(Review of hepatotoxicity of drugs of abuse mentions that hepatotoxicity from buprenorphine is rare when used in recommended sublingual doses, but that severe reactions occur when used by the intravenous route, possibly as a result of mitochondrial injury).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.yaksh.2018">Yaksh T, Wallace M. Opioids, analgesia, and pain management. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 355-386.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.hirschauer.1989.636">Hirschauer C, Guillemot F, H&#x000e9;ud M, Mathieu-Chandelier C, Cortot A, Paris JC. <span><span class="ref-journal">Gastroenterol Clin Biol. </span>1989;<span class="ref-vol">13</span>:636.</span> [Is buprenorphine hepatotoxic?] French. [<a href="/pubmed/2753313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2753313</span></a>]<div><i>(36 year old man developed abnormal liver tests 3 months after starting buprenorphine for chronic pain [bilirubin 0.6 mg/dL, ALT 100 U/L, GGT 899 U/L], resolving rapidly, but rising again on rechallenge [ALT 52 U/L]; biopsy showed steatosis and inflammation, and the patient admitted to alcohol use [50 g/day]).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.houdret.1999.29">Houdret N, Asnar V, Szostak-Talbodec N, Leteurtre E, Humbert L, Lecomte-Houcke M, Lhermitte M, Paris JC. <span><span class="ref-journal">Acta Clin Belg. </span>1999;<span class="ref-vol">53</span> Suppl 1:29–31.</span> [Hepatonephritis and massive ingestion of buprenorphine] French. [<a href="/pubmed/10216978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10216978</span></a>]<div><i>(33 year old man developed hepatic and renal failure 1-2 days after taking an overdose of buprenorphine [112 mg] [bilirubin 5.5 mg/dL, ALT 11,080 U/L, Alk P 334 U/L, prothrombin index 20%, creatinine 8.0 mg/dL], with subsequent rapid and complete recovery).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.berson.2001.346">Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P, et al.  Hepatitis after intravenous buprenorphine misuse in heroin addicts. <span><span class="ref-journal">J Hepatol. </span>2001;<span class="ref-vol">34</span>:346–50.</span> [<a href="/pubmed/11281569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11281569</span></a>]<div><i>(Five cases of acute hepatitis-like injury in male heroin users, ages 25 to 34 years, arising after 2-8 weeks of buprenorphine therapy, 4 admitted to iv injection [bilirubin 0.8-11 mg/dL, ALT 520-6595 U/L, Alk P 126-306 U/L], one with hepatic failure, rapidly resolving, but all 5 had chronic hepatitis C, one had concurrent hepatitis B and one had HIV infection; several were continued on sublingual buprenorphine without recurrence).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.wisniewski.2001.328">Wisniewski B, Perlemuter G, Buffet C. <span><span class="ref-journal">Gastroenterol Clin Biol. </span>2001;<span class="ref-vol">25</span>:328–9.</span> [Acute hepatitis following intravenous buprenorphine injection as a substitute drug in a drug-addict] French. [<a href="/pubmed/11395686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11395686</span></a>]<div><i>(25 year old with chronic hepatitis C and heroin use developed jaundice 72 hours after injecting buprenorphine intravenously [bilirubin 4.3 mg/dL, ALT 31 times ULN, Alk P 2.5 times ULN, HCV RNA positive], biopsy showing acute hepatitis and cholestasis; rapid recovery).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.petitjean.2001.97">Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. <span><span class="ref-journal">Drug Alcohol Depend. </span>2001;<span class="ref-vol">62</span>:97–104.</span> [<a href="/pubmed/11173173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11173173</span></a>]<div><i>(Controlled trial comparing methadone to buprenorphine in 58 patients with opioid dependence found poorer retention rate with buprenorphine; no hepatotoxicity reported).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.vidaltrecan.2003.175">Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. <span><span class="ref-journal">Drug Alcohol Depend. </span>2003;<span class="ref-vol">69</span>:175–81.</span> [<a href="/pubmed/12609698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12609698</span></a>]<div><i>(Survey of 404 subjects on maintenance buprenorphine for opiate abuse found that 46% admitted to illicit intravenous self-administration).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.mattick.2003.441">Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <span><span class="ref-journal">Addiction. </span>2003;<span class="ref-vol">98</span>:441–52.</span> [<a href="/pubmed/12653814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12653814</span></a>]<div><i>(Controlled trial in 405 patients with opioid dependence found similar rates of adverse events with buprenorphine and methadone; one patient had hepatitis C, but no other liver related adverse events reported).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.fudala.2003.949">Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, et al.  Buprenorphine/Naloxone Collaborative Study Group Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>:949–58.</span> [<a href="/pubmed/12954743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12954743</span></a>]<div><i>(Controlled trial of buprenorphine/naloxone vs buprenorphine alone vs placebo for 4 weeks in 326 opiate addicted patients; ALT elevations occurred in 10 patients, but 8 had concurrent hepatitis B or C).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.herv_.2004.1033">Herv&#x000e9; S, Riachi G, Noblet C, Guillement N, Tanasescu S, Goria O, Thuillez C, et al.  Acute hepatitis due to buprenorphine administration. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2004;<span class="ref-vol">16</span>:1033–7.</span> [<a href="/pubmed/15371928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15371928</span></a>]<div><i>(7 cases of hepatotoxicity attributed to buprenorphine, all heroin addicts, 6 men and 1 woman, ages 24 to 38 years on buprenorphine [2-12 mg/day] for 4-20 weeks, sublingual in 6 and by injection in one, all had anti-HCV and 2 HCV RNA, 2 HBsAg [ALT 9 to 68 times ULN], 5 with jaundice [bilirubin levels not given]; all recovered rapidly despite continuing buprenorphine [at reduced doses in 3]).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.zuin.2009.e8">Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A, Benetti A, et al.  Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. <span><span class="ref-journal">Dig Liver Dis. </span>2009;<span class="ref-vol">41</span>:e8–e10.</span> [<a href="/pubmed/18294936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18294936</span></a>]<div><i>(33 year old man with chronic hepatitis C and heroin use developed jaundice 3 weeks after starting sublingual buprenorphine [20 mg daily] [bilirubin 8.4 mg/dL, ALT 300 times ULN, INR 3.1, creatinine 4.6, HCV RNA positivity], but rapid recovery and ALT levels normal and HCV RNA negative in follow-up).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.peyri_re.2009.973">Peyri&#x000e8;re H, Tatem L, Bories C, Pageaux GP, Blayac JP, Larrey D. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. <span><span class="ref-journal">Ann Pharmacother. </span>2009;<span class="ref-vol">43</span>:973–7.</span> [<a href="/pubmed/19383935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19383935</span></a>]<div><i>(Two male injection drug users, 33 and 50 years old, with chronic hepatitis C presented with jaundice after injecting buprenorphine [bilirubin 29.6 and 2.1 mg/dL, ALT 4132 and 866 U/L, Alk P 347 and 1028 U/L], resolving rapidly and associated with loss of HCV RNA: Case 1).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.orman.2009.577">Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. <span><span class="ref-journal">Drugs. </span>2009;<span class="ref-vol">69</span>:577–607.</span> [<a href="/pubmed/19368419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19368419</span></a>]<div><i>(Review of the pharmacology, safety and efficacy of the combination of buprenorphine and naloxone as therapy of opioid dependence; no report of clinically apparent liver injury in preregistration clinical trials).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.pinto.2010.340">Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. <span><span class="ref-journal">J Subst Abuse Treat. </span>2010;<span class="ref-vol">39</span>:340–52.</span> [<a href="/pubmed/20817384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20817384</span></a>]<div><i>(Patient preference controlled trial comparing buprenorphine and methadone for up to 6 months in 361 opiate dependent subjects; no discussion of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none to buprenorphine or other agents used to treat substance abuse).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.vergararodriguez.2011.s62">Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, et al.  BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2011;<span class="ref-vol">56</span> Suppl 1:S62–7.</span> [<a href="/pubmed/21317596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21317596</span></a>]<div><i>(Among 141 HIV infected subjects treated with buprenorphine/naloxone for 6 months, median serum ALT and AST values did not change and no patient developed clinically apparent liver injury, 3 had transient ALT elevations during treatment [383, 123 and 218 U/L], but all resolved either spontaneously or with drug discontinuation).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.dasgupta.2010.1078">Dasgupta N, Bailey EJ, Cicero T, Inciardi J, Parrino M, Rosenblum A, Dart RC. Post-marketing surveillance of methadone and buprenorphine in the United States. <span><span class="ref-journal">Pain Med. </span>2010;<span class="ref-vol">11</span>:1078–91.</span> [<a href="/pubmed/20545875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20545875</span></a>]<div><i>(Between 2003 and 2007 there were increases in the rates of abuse and diversion of both methadone and buprenorphine in the US, the rates being higher for methadone).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.upadhyay.2010.545">Upadhyay A, Xueming Y. Buprenorphine-induced elevated liver enzymes in an adolescent patient. <span><span class="ref-journal">J Child Adolesc Psychopharmacol. </span>2010;<span class="ref-vol">20</span>:545–6.</span> [<a href="/pubmed/21186976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21186976</span></a>]<div><i>(17 year old girl developed abdominal pain and enzyme elevations 9 days after starting buprenorphine with naloxone [bilirubin normal, ALT 452 U/L, anti-HCV negative], resolving rapidly on stopping; also taking quetiapine and tizanidine).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.bogenschutz.2010.211">Bogenschutz MP, Abbott PJ, Kushner R, Tonigan JS, Woody GE. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. <span><span class="ref-journal">J Addict Med. </span>2010;<span class="ref-vol">4</span>:211–6.</span> [<a href="/pmc/articles/PMC3002235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3002235</span></a>] [<a href="/pubmed/21170166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21170166</span></a>]<div><i>(Among 152 patients with opioid dependence treated with 2 vs 12 weeks of buprenorphine with naloxone, ALT elevations occurred in 13% vs 23% of patients, but were mostly attributed to underlying HCV infection).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.kraus.2011.254">Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, et al.  Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. <span><span class="ref-journal">J Addict Med. </span>2011;<span class="ref-vol">5</span>:254–63.</span> [<a href="/pubmed/22042215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22042215</span></a>]<div><i>(Guidelines and recommendations for use of buprenorphine in office based practice; no discussion of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.steiner.2011.903">Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-na&#x000ef;ve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. <span><span class="ref-journal">J Pain Symptom Manage. </span>2011;<span class="ref-vol">42</span>:903–17.</span> [<a href="/pubmed/21945130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21945130</span></a>]<div><i>(541 patients with severe low back pain were randomized to receive transdermal buprenorphine or placebo for 12 weeks; overall, clinical laboratory test results did not change on buprenorphine treatment).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.amass.2012.142">Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, et al.  A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. <span><span class="ref-journal">Addiction. </span>2012;<span class="ref-vol">107</span>:142–51.</span> [<a href="/pubmed/21749526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21749526</span></a>]<div><i>(Among 187 injection drug users treated for 4 weeks with buprenorphine with naloxone, common side effects included insomnia, sweating, nausea and anxiety, but all serious adverse events were considered unrelated; no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.ray.2012.359">Ray R, Vaswani M, Deb KS, Sethi H, Chopra A, Kishore N, Goyal R. Post marketing surveillance of sublingual buprenorphine naloxone combination tablets. <span><span class="ref-journal">Indian J Physiol Pharmacol. </span>2012;<span class="ref-vol">56</span>:359–66.</span> [<a href="/pubmed/23781656" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23781656</span></a>]<div><i>(Among 158 patients with opioid dependence treated with buprenorphine with naloxone, liver enzyme elevations were reported in 52% of patients, but none was associated with severe hepatitis).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.saxon.2013.71">Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, et al.  Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. <span><span class="ref-journal">Drug Alcohol Depend. </span>2013;<span class="ref-vol">128</span>:71–6.</span> [<a href="/pmc/articles/PMC3543467/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3543467</span></a>] [<a href="/pubmed/22921476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22921476</span></a>]<div><i>(Among 731 patients with opioid dependency treated with either buprenorphine with naloxone or methadone for at least 24 weeks, 12.6% vs 17.9% developed ALT elevations [&#x0003e;2 times ULN], which were "extreme" in only 2.1% vs 3.6% [bilirubin 0.7-3.7 mg/dL, ALT 418-6280 U/L], usually attributable to underlying HBV or HCV infection, but specific details were not provided).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.soyka.2014.563">Soyka M, Backmund M, Schmidt P, Apelt S. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. <span><span class="ref-journal">Am J Addict. </span>2014;<span class="ref-vol">23</span>:563–9.</span> [<a href="/pubmed/25251050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25251050</span></a>]<div><i>(Among 188 opioid dependent patients treated with buprenorphine/naloxone for 12 months, 1-2% had liver enzyme elevations that were &#x0201c;mostly discrete&#x0201d; [all less than 100 U/L], transient and without jaundice or symptoms).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.lucas.2014.139">Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, et al. HPTN 058 study group.  Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. <span><span class="ref-journal">Drug Alcohol Depend. </span>2014;<span class="ref-vol">142</span>:139–45.</span> [<a href="/pmc/articles/PMC4127183/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4127183</span></a>] [<a href="/pubmed/24999060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24999060</span></a>]<div><i>(Among 1036 patients with opioid use disorder treated with buprenorphine/naloxone in short [18 day] or long [52 week] courses, serum ALT elevations above 3 times ULN arose in 76 patients [7%], most instances occurring with either acute or chronic HCV infection and rates of ALT elevations were similar with either short and long term use, as well as after discontinuation of the medication).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.nasser.2015.837">Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh Classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. <span><span class="ref-journal">Clin Pharmacokinet. </span>2015;<span class="ref-vol">54</span>:837–49.</span> [<a href="/pubmed/25603822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25603822</span></a>]<div><i>(Pharmacokinetic study of sublingual buprenorphine and naloxone in 33 patients with variable degrees of hepatic dysfunction identified higher plasma concentrations of both agents in patients with moderate or severe dysfunction (Child&#x02019;s Pugh B and C], but not in those with mild dysfunction or chronic HCV infection without cirrhosis; side effects included dizziness, nausea, fatigue and pruritus but there were &#x0201c;no post-dose findings of clinical relevance in clinical laboratory&#x0201d; tests ).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.french.2015.705">French J, Mujumdar A, Angus P, Gow P. Fulminant hepatic failure after intravenous injection of sublingual buprenorphine in a patient with hepatitis C. <span><span class="ref-journal">Clin Case Rep. </span>2015;<span class="ref-vol">3</span>:705–6.</span> [<a href="/pmc/articles/PMC4551330/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4551330</span></a>] [<a href="/pubmed/26331017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26331017</span></a>]<div><i>(20 year old indigenous Australian male with known chronic hepatitis C and injection drug abuse developed severe hepatitis with jaundice arising a day after injecting buprenorphine/naloxone meant for sublingual use [bilirubin 13.8 mg rising to 26.4 mg/dL, ALT 8768 U/L, INR 9, lactate 5.6 ], with rapid recovery with medical management, no follow up of HCV status after recovery).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.ciftci_demirci.2015.107">Ciftci Demirci A, Gunes H, Adaletli H, Bulanik E, Erdogan A. Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents. <span><span class="ref-journal">Am J Drug Alcohol Abuse. </span>2015;<span class="ref-vol">41</span>:107–13.</span> [<a href="/pubmed/25490611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25490611</span></a>]<div><i>(Among 59 heroin-dependent adolescents started on buprenorphine/naloxone, mean serum ALT and AST levels rose by week 2 but returned to baseline levels by week 8 of therapy; one patient developed acute hepatitis C during treatment).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.tetrault.2016.62">Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V 3rd, Lim JK, Rimland D, et al.  Hepatic safety of buprenorphine in HIV-infected and uninfected patients with opioid use disorder: the role of HCV-infection. <span><span class="ref-journal">J Subst Abuse Treat. </span>2016;<span class="ref-vol">68</span>:62–7.</span> [<a href="/pmc/articles/PMC4976086/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4976086</span></a>] [<a href="/pubmed/27431048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27431048</span></a>]<div><i>(Among 666 patients [mostly men] identified in a Veterans Administration electronic medical database who were started on buprenorphine and were monitored, 14 developed &#x0201c;drug-induced liver injury&#x0201d;, all of whom had received a potentially hepatotoxic medication [93%] or had preexisting HCV infection [7%], and there was no overall &#x0201c;substantial&#x0201d; change in serum ALT, AST or bilirubin levels).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.aldemir.2016.2769">Aldemir E, Coskunol H, Kilic M, Sert I. Treatment of opioid dependence with buprenorphine/naloxone after liver transplantation: Report of two cases. <span><span class="ref-journal">Transplant Proc. </span>2016;<span class="ref-vol">48</span>:2769–72.</span> [<a href="/pubmed/27788815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27788815</span></a>]<div><i>(Two patients with liver transplants for chronic hepatitis C and opioid use disorder were treated successfully with buprenorphine/naloxone with no significant side effects or worsening of minimal ALT and AST elevations due to recurrent hepatitis C ).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF35">Buprenorphine implants (Probuphine) for opioid dependence. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2016;<span class="ref-vol">58</span>(1499):94–5.</span> [<a href="/pubmed/27403784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27403784</span></a>]<div><i>(Concise summary of the mechanism of action, efficacy, safety and costs of a subdermally administered implant that provides plasma levels of buprenorphine for 6 months and appears to be similar in efficacy to transdermal or buccal administration, but has added adverse effects such as injury from the insertion and removal of the implant; mentions that hepatotoxicity has occurred with buprenorphine therapy).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF36">Buprenorphine buccal film (Belbuca) for chronic pain. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2016;<span class="ref-vol">58</span>(1492):47–8.</span> [<a href="/pubmed/27049508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27049508</span></a>]<div><i>(Concise summary of the mechanism of action, efficacy, safety and costs of a new formulation of buprenorphine provided as a buccal film).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.pergolizzi.2017.92">Pergolizzi JV, Raffa RB, Marcum Z, Colucci S, Ripa SR. Safety of buprenorphine transdermal system in the management of pain in older adults. <span><span class="ref-journal">Postgrad Med. </span>2017;<span class="ref-vol">129</span>:92–101.</span> [<a href="/pubmed/27929709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27929709</span></a>]<div><i>(Review of the literature on the safety and efficacy of buprenorphine in elderly patients mentions that liver abnormalities are rare [&#x0003c;1%] and ALT values above 3 times ULN occur in only 0.2% of both elderly and younger adults).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.concheiro.2018.1210">Concheiro M, Chesser R, Pardi J, Cooper G. Postmortem toxicology of new synthetic opioids. <span><span class="ref-journal">Front Pharmacol. </span>2018;<span class="ref-vol">9</span>:1210.</span> [<a href="/pmc/articles/PMC6212520/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6212520</span></a>] [<a href="/pubmed/30416445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30416445</span></a>]<div><i>(Summary of the chemical structures, pharmacology, relative potency and toxicology of the major synthetic opioids implicated in the ongoing opioid overdose epidemic; no discussion of hepatic injury).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF.grebely.2018.ofy001">Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, et al.  Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies. <span><span class="ref-journal">Open Forum Infect Dis. </span>2018;<span class="ref-vol">5</span>:ofy001. </span> [<a href="/pmc/articles/PMC5808802/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5808802</span></a>] [<a href="/pubmed/29450210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29450210</span></a>]<div><i>(Among 4743 patients enrolled in phase 3 trials of direct acting antiviral agents for HCV, 194 [4%] were on opioid substitution therapy including 75 on buprenorphine or buprenorphine/naloxone; the sustained virologic response rate was similar in those receiving buprenorphine [96%] to that in those who were not on any substitution therapy [97%] and adverse event rates were also similar).</i></div></div></li><li><div class="bk_ref" id="Buprenorphine.REF40">Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2018;<span class="ref-vol">60</span>(1541):35–7.</span> [<a href="/pubmed/29485976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29485976</span></a>]<div><i>(Concise review of the mechanism of action, efficacy, safety and costs of a once-monthly formulation of buprenorphine given subcutaneously and providing plasma levels similar to those with sublingual buprenorphine, mentions that serum aminotransferase elevations are frequent with its use).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548871</span><span class="label">PMID: <a href="/pubmed/31644178" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644178</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Budesonide/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Bupropion/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548871&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548871/?report=reader">PubReader</a></li><li><a href="/books/NBK548871/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548871" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548871" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Buprenorphine. [Updated 2020 Nov 24].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548871/pdf/Bookshelf_NBK548871.pdf">PDF version of this page</a> (134K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Buprenorphine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Buprenorphine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Buprenorphine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Buprenorphine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4856952" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4856952" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4856952" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643200" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Opioids</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Opioids<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10928310" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.</a><span class="source">[Psychopharmacology (Berl). 2000]</span><div class="brieflinkpop offscreen_noflow">Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Strain EC, Stoller K, Walsh SL, Bigelow GE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Psychopharmacology (Berl). 2000 Mar; 148(4):374-83. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26412801" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.</a><span class="source">[Clin Ther. 2015]</span><div class="brieflinkpop offscreen_noflow">Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gunderson EW, Hjelmström P, Sumner M, 006 Study Investigators.. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ther. 2015 Oct 1; 37(10):2244-55. Epub 2015 Sep 26.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25610012" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.</a><span class="source">[Subst Abuse Rehabil. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Soyka M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Subst Abuse Rehabil. 2015; 6:1-14. Epub 2015 Jan 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8889672" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.</a><span class="source">[J Anal Toxicol. 1996]</span><div class="brieflinkpop offscreen_noflow">Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Anal Toxicol. 1996 Oct; 20(6):369-78. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644178" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644178" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467a729e31203af6468e59">Buprenorphine - LiverTox</a><div class="ralinkpop offscreen_noflow">Buprenorphine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:26:42-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B320904669E310000000003930110&amp;ncbi_session=CE8B32090467A711_0915SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548871%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548871&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548871/&amp;ncbi_pagename=Buprenorphine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B32090467A711_0915SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>